422 million adults worldwide have diabetes and 48% of all juvenile deaths are due to diabetes or diabetes-inflicted diseases; diabetes in low-income families has risen rapidly — 21% since 2010. By combining recent advances in microRNA (miR) technology, applying a novel miR-based LNP loading and microneedle hyaluronic chain-linked drug-infusion method, DiaMiR (Diabetes MicroRNA-injected Reparation) aims to mitigate the adverse effects of Type-2 Diabetes (T2D) by activating T2D-inhibited signaling pathways through relevant cell targeting. This study provides proof of concept, in-vitro, and in-vivo data for developing a cost-effective and accessible miR-loaded wearable microneedle patch to control T2D, significantly lowering blood glucose levels in diabetics for 3-4 days.